Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 9/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812910 | 0.90 | CTSA (0.54) | CTSAMMP8ALDH1A1MAPT | |
| SCHEMBL7102817 | 0.82 | MMP8 (0.42) | CTSAMMP8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1274812 | 0.80 | CTSA (0.52) | CTSASCN9ADAGLBDAGLABCL2L1 | |
| SCHEMBL1274836 | 0.78 | MEN1 (0.45) | CTSAMAPT | |
| SCHEMBL9052329 | 0.77 | MMP8 (0.50) | MMP8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1274076 | 0.76 | AOC3 (0.44) | CTSACDC7DBF4ALDH1A1LMNA | |
| Ethyl Acetate SCHEMBL27263183 | 0.75 | CDC7 (0.45) | CTSACDC7DBF4ALDH1A1LMNA | |
| Ethyl Acetate SCHEMBL27447758 | 0.74 | CDC7 (0.44) | CTSACDC7DBF4ALDH1A1LMNA | |
| Ethyl Acetate SCHEMBL27778289 | 0.74 | CDC7 (0.44) | CTSACDC7DBF4ALDH1A1LMNA | |
| SCHEMBL1491141 | 0.74 | MMP8 (0.53) | MMP8ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462124-B9 | MESOIONIC PESTICIDES | DU PONT (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9596856-B2 | Mesoionic pesticides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160066577-A1 | MESOIONIC PESTICIDES | FMC CORPORATION | 2016-03-10 | — | — | US | disclosed |
| US-9210932-B2 | Mesoionic pesticides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140206536-A1 | MESOIONIC PESTICIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722690-B2 | Mesoionic pesticides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2462124-B1 | MESOIONIC PESTICIDES | DU PONT (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120277100-A1 | MESOIONIC PESTICIDES | FMC CORPORATION | 2012-11-01 | — | — | US | disclosed |
| EP-2462124-A2 | MESOIONIC PESTICIDES | E. I. du Pont de Nemours and Company (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011017342-A2 | MESOIONIC PESTICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206536-A1 | MESOIONIC PESTICIDES | CHRM3, CHRM2, CHRM5 | CTSA 2585/4885CDC7 1736/4885DBF4 2435/4885 |
| US-20160066577-A1 | MESOIONIC PESTICIDES | CHRM3, CHRM2, CHRM5 | CTSA 2585/4885CDC7 1736/4885DBF4 2435/4885 |
| US-20120277100-A1 | MESOIONIC PESTICIDES | CHRM3, CHRM2, CHRM5 | CTSA 2655/4885CDC7 1664/4885DBF4 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.